Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.2.885

miR-27a as an Oncogenic microRNA of Hepatitis B Virus-related Hepatocellular Carcinoma  

Wu, Xin-Jun (Department of General Surgery II, The First Affiliated Hospital of Xinxiang Medical University)
Li, Yan (Department of General Surgery II, The First Affiliated Hospital of Xinxiang Medical University)
Liu, Dong (Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University)
Zhao, Lun-De (Department of General Surgery II, The First Affiliated Hospital of Xinxiang Medical University)
Bai, Bin (Department of General Surgery II, The First Affiliated Hospital of Xinxiang Medical University)
Xue, Ming-Hui (Department of General Surgery II, The First Affiliated Hospital of Xinxiang Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.2, 2013 , pp. 885-889 More about this Journal
Abstract
microRNAs (miRNAs) are small non-coding RNAs that regulate gene expression through post-transcriptional interactions with mRNA. miRNAs have recently emerged as key regulators of various cancers. Although miR-27a has been implicated in several other cancers, its role in hepatitis B virus-related hepatocellular carcinoma (HCC) is unknown. In this study, we showed miR-27a to be frequently up-regulated in HCC tissues and HCC cell lines (HepG2 and Huh7). Overexpression of miR-27a enhanced cell proliferation, promoted migration and invasion, and activated cell cycling in HepG2 and Huh7 cells. In summary, our results suggest that up-regulation of miR-27a may play an oncogenic role in the development of HCC and might thus be a new therapeutic target in HCC patients.
Keywords
Hepatocellular carcinoma; microRNA; miR-27a; proliferation; migration and invasion;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ma Y, Yu S, Zhao W, Lu Z, Chen J (2010). miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett, 298, 150-8.   DOI   ScienceOn
2 McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A (2011). Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem, 57, 833-40.   DOI   ScienceOn
3 Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S (2007). The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res, 67, 11001-11.   DOI   ScienceOn
4 Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 105, 10513-8.   DOI   ScienceOn
5 Schrauder MG, Strick R, Schulz-Wendtland R, et al (2012). Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One, 7, e29770.   DOI
6 Szafranska AE, Davison TS, John J, et al (2007). MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene, 26, 4442-52.   DOI   ScienceOn
7 Tinkle CL, Haas-Kogan D (2012). Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics, 6, 207-19.
8 Zheng D, Haddadin S, Wang Y, et al (2011). Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol, 4, 575-86.
9 Zhou J, Yu L, Gao X, et al (2011). Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 29, 4781-8.   DOI   ScienceOn
10 Zinkin NT, Grall F, Bhaskar K, et al (2008). Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res, 14, 470-7.   DOI   ScienceOn
11 Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.   DOI   ScienceOn
12 Brase JC, Johannes M, Schlomm T, et al (2011). Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer, 128, 608-16.   DOI   ScienceOn
13 Budhu A, Jia HL, Forgues M, et al (2008). Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology, 47, 897-907.   DOI   ScienceOn
14 Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.   DOI   ScienceOn
15 Chintharlapalli S, Papineni S, Abdelrahim M, et al (2009). Oncogenic microRNA-27a is a target for anticancer agent methyl2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer, 125, 1965-74.   DOI   ScienceOn
16 El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008). Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology, 134, 1752-63.   DOI   ScienceOn
17 Garzon R, Calin GA, Croce CM (2009). MicroRNAs in Cancer. Annu Rev Med, 60, 167-79.   DOI   ScienceOn
18 Gottardo F, Liu CG, Ferracin M, et al (2007). Micro-RNA profiling in kidney and bladder cancers. Urol Oncol, 25, 387-92.   DOI   ScienceOn
19 Guttilla IK, White BA (2009). Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem, 284, 23204-16.   DOI   ScienceOn
20 Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.   DOI   ScienceOn
21 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
22 Ji J, Shi J, Budhu A, et al (2009). MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 361, 1437-47.   DOI   ScienceOn
23 Ladeiro Y, Couchy G, Balabaud C, et al (2008). MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 47, 1955-63.   DOI   ScienceOn
24 Jiang J, Gusev Y, Aderca I, et al (2008). Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res, 14, 419-27.   DOI   ScienceOn
25 Kasinski AL, Slack FJ (2011). MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer, 11, 849-64.   DOI   ScienceOn
26 Kutay H, Bai S, Datta J, et al (2006). Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem, 99, 671-8.   DOI   ScienceOn
27 Lerner M, Lundgren J, Akhoondi S, et al (2011). MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle, 10, 2172-83.   DOI
28 Li LM, Hu ZB, Zhou ZX, et al (2010). Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res, 70, 9798-807.   DOI
29 Liu H, Zhu L, Liu B, et al (2012). Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett, 316, 196-203.   DOI   ScienceOn
30 Liu T, Tang H, Lang Y, Liu M, Li X (2009). MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett, 273, 233-42.   DOI   ScienceOn
31 Li W, Xie L, He X, et al (2008). Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer, 123, 1616-22.   DOI   ScienceOn
32 Li Z, Hu S, Wang J, et al (2010). MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol, 119, 125-30.   DOI   ScienceOn